Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
- Collaboration with Merck KGaA could generate up to $674 million in milestone payments for Exscientia
- Exscientia to receive upfront cash payment of $20 million
- Potential for tiered royalties on product sales for Exscientia
- None.
Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges
Exscientia is eligible to receive up to
Up to
Three potential first-in-class or best-in-class targets have been identified as the initial focus of the partnership. The collaboration allows Merck KGaA, Darmstadt,
“We’re pleased that Merck KGaA, Darmstadt,
Under the terms of the agreement, Exscientia will receive an upfront cash payment of
About Exscientia
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
Forward-looking statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the initiation and duration of Exscientia’s collaboration with Merck and the activities undertaken in connection with the collaboration. Any statement describing Exscientia’s goals, plans, expectations, projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the success of Exscientia's collaboration with Merck. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919108369/en/
Investor Relations Contact:
Sara Sherman
investors@exscientia.ai
Media Contact:
Oliver Stohlmann
media@exscientia.ai
Source: Exscientia plc